BioLineRx (BLRX) Revenue (2024 - 2025)
BioLineRx (BLRX) posted quarterly Revenue of $194000.0 for Q4 2025, down 98.35% year-over-year from $11.7 million in Q4 2024, and down 54.57% quarter-over-quarter from $427000.0 in Q3 2025.
BioLineRx (BLRX) Revenue (2024 - 2025) Analysis & Trends
BioLineRx's Revenue history runs 2 years deep, the most recent figure standing at $194000.0 for Q4 2025.
- In Q4 2025, Revenue fell 98.35% year-over-year to $194000.0; the TTM figure through Dec 2025 stood at $1.2 million (down 95.92% YoY), while the FY2025 annual figure was $1.2 million, down 95.92% from the prior year.
- Revenue for Q4 2025 stood at $194000.0, down from $427000.0 in the prior quarter.
- The five-year high for Revenue was $11.7 million in Q4 2024, with the low at $194000.0 in Q4 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | BioLineRx | 7.21 Bn | 7.21 Bn | 154,000.00 | 194,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 194,000.00 |
| Sep 30, 2025 | 427,000.00 |
| Jun 30, 2025 | 304,000.00 |
| Mar 31, 2025 | 255,000.00 |
| Dec 31, 2024 | 11.75 Mn |
| Sep 30, 2024 | 4.94 Mn |
| Jun 30, 2024 | 5.39 Mn |
| Mar 31, 2024 | 6.86 Mn |